Good morning, it's Jack & Paul here with the SCVR for Thursday.

Agenda - many thanks to Jack for covering the morning shift, with;

Ekf Diagnostics Holdings (LON:EKF) - 2 announcements

Tclarke (LON:CTO) - Trading update

Paul is doing the afternoon shift, and will be looking at;

Boohoo (LON:BOO) - Update on supply chain action, including appointing KPMG & Lord Leveson

Tracsis (LON:TRCS) - Final results

Shoe Zone (LON:SHOE) - Update buried in a "Date of results" announcement

Newriver Reit (LON:NRR) - Half year results - sorry, ran out of time, see Friday's report.

Motorpoint (LON:MOTR) - Interim results - sorry, ran out of time, see Friday's report.

(and possibly circling back to De La Rue (LON:DLAR) from yesterday, or I might do that tomorrow, it depends on time)

Timing - estimated time of completion, c.7pm. (extended, because I want to watch the webinar from Intercede at 16:15 on IMC). Today's report is now finished.


Jack's section

EKF Diagnostics (LON:EKF)

Share price: 63.17p (+4.41%)

Shares in issue: 454,993,227

Market cap: £287.4m

We last talked about Ekf Diagnostics Holdings (LON:EKF) here, on the 9th of November - a ‘comfortably ahead’ trading update - but this was just before the first of the vaccine news.

Those stories seem to have sparked a fundamental rotation in market sentiment. This might last, or it might not, but it’s interesting to track EKF’s share price movements this month, up nearly 20% at one point before handing momentum over to the FTSE 100.

kU8wvPpVOttbk46Z5GP6jShuGmz9Be5vaY7ye33aQeirfxvzMEg9FYUZCSoXKGvbSHbjzXhAy5eSusQeCrId6KOf-sdWHDyQTEhr78a44Sb4ajxV1tAzBJIc_tgfH8yF-olmKuDN

EKF is a global, integrated medical diagnostics business that designs and manufactures diagnostic equipment for use within Point-of-Care settings. Its portfolio includes small blood analysers used in testing patients for conditions including diabetes and anaemia.

As a transporter of Covid samples, its business has benefitted from recent conditions with the release of its PrimeStore MTM pathogenic sample collection product. Even now, the shares retain a punchy valuation of 29.8 times forecast earnings. This is based on FY21 numbers, though.

Brokers are forecasting a bumper FY20, with earnings set to come in at 3.41p, making for a more reasonable valuation of 18.8 times current year earnings.

As with other stocks, the question…

Unlock the rest of this Article in 15 seconds

or Unlock with your email

Already have an account?
Login here